Global Conference 2011

As the science behind genomics matures and the promise of therapies targeted to individual patients nears, the realities of developing, approving and ultimately paying for drugs geared to targeted populations requires a new paradigm of clinical research and care. What kind of model will work as we move forward to transition drugs through the regulatory and reimbursement environment?


Greg Simon

Senior Vice President, Patient Engagement, Pfizer Inc.


Paul Billings

Chief Medical Officer, Life Technologies

Laura Esserman

Director, Carol Franc Buck Breast Care Center, Professor of Surgery and Radiology, UCSF

Ricardo Guggenheim

Vice President, Care Management Strategy, McKesson Health Solutions

Scott Jenkins

Area Vice President, Healthcare and Life Sciences Solution Sales, Dell

Return to Program Detail